Synthesis and Biological Evaluation of RGD-Conjugated MEK1/2 Kinase Inhibitors for Integrin-Targeted Cancer Therapy

Protected Maleimide Building Blocks for the Decoration of Peptides, Peptoids, and Peptide Nucleic Acids

(2013) Xavier Elduque et al.   BIOCONJUGATE CHEMISTRY

RGD-Based Strategies To Target Alpha(v) Beta(3) Integrin in Cancer Therapy and Diagnosis

(2012) Fabienne Danhier et al.   MOLECULAR PHARMACEUTICS

Integrin Targeted Delivery of Gene Therapeutics

(2012) Rudy L Juliano et al.   Theranostics

Synthesis, in vitro screening and in vivo evaluation of cyclic RGD analogs cyclized through oxorhenium and oxotechnetium coordination

(2011) Marie Aufort et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Structure-based design and synthesis of pyrrole derivatives as MEK inhibitors

(2010) Michael B. Wallace et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Chemical affinity matrix-based identification of prohibitin as a binding protein to anti-resorptive sulfonyl amidine compounds

(2010) Sung-Youn Chang et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

(2010) E. B. Haura et al.   CLINICAL CANCER RESEARCH

Peptide-mediated targeted drug delivery

(2010) Sumit Majumdar et al.   MEDICINAL RESEARCH REVIEWS

MEK Inhibitor PD0325901 Significantly Reduces the Growth of Papillary Thyroid Carcinoma Cells In vitro and In vivo

(2010) Y. C. Henderson et al.   MOLECULAR CANCER THERAPEUTICS

Targeting the RAF–MEK–ERK pathway in cancer therapy

(2009) Clara Montagut et al.   CANCER LETTERS

Construction of Carbo- and Heterocycles Using Radical Relay Cyclizations Initiated by Alkoxy Radicals

(2009) Hai Zhu et al.   ORGANIC LETTERS

The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901

(2008) Stephen D. Barrett et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced Cancers

(2008) Alex A. Adjei et al.   JOURNAL OF CLINICAL ONCOLOGY